Results 101 to 110 of about 2,265 (159)

Hypophosphatemia in the Diagnosis and Management of Primary Hyperparathyroidism. [PDF]

J Clin Med
Cano-Mármol RP, Ros-Madrid I, Andreo-López MC, Muñoz-Torres M.   +3 more
europepmc   +1 more source

Long-Term Effects of Early Low-Phosphorous Nutritional Conditioning on Broiler Chicken Performance, Bone Mineralization, and Gut Health Under Adequate or Phosphorous-Deficient Diets. [PDF]

Animals (Basel)
Tous N, Francesch M, Tarradas J, Badiola I, Pérez de Rozas AM, Fàbrega E, Ballester M, Quintanilla R, Torrallardona D.   +8 more
europepmc   +1 more source

Pulmonary Alveolar Microlithiasis: Case Report. [PDF]

Open Respir Arch
Jiménez Romero AA, Hernandez Caler R, Martinez Garceran JJ, Blasco Muñoz S.   +3 more
europepmc   +1 more source

Role of ABCC5 in cancer drug resistance and its potential as a therapeutic target. [PDF]

Front Cell Dev Biol
Pan Y, Wu M, Cai H.
europepmc   +1 more source

Case Series: EGFR and ROS-1 Co-Occurrence in Advanced Non-Small Cell Lung Cancer. [PDF]

J Immunother Precis Oncol
Alfayea T, Salim AA, Alkaiyat M, Al-Rehaily S.   +3 more
europepmc   +1 more source

Role of solute carrier transporters in ovarian cancer (Review). [PDF]

Int J Mol Med
Quaresima B, Scicchitano S, Faniello MC, Mesuraca M.   +3 more
europepmc   +1 more source

A novel tumor-associated macrophage risk signature predicts prognosis and immunotherapy response in lung adenocarcinoma. [PDF]

Am J Cancer Res
Zhu Y, Song Y, Jiang W, Zhang J, Yin L, Lin X, Lu Y, Tao D, Ma Y.   +8 more
europepmc   +1 more source

Transcriptomic analysis of ROS1+ non-small cell lung cancer reveals an upregulation of nucleotide synthesis and cell adhesion pathways. [PDF]

Front Oncol
Terrones M, Op de Beeck K, Van Camp G, Vandeweyer G, Mateiu L.   +4 more
europepmc   +1 more source

<i>NAT2</i>: A Novel Target in Intrahepatic Cholangiocarcinoma and its Role in Modulating Tumor Behavior. [PDF]

Clin Med Insights Oncol
Chen X, Yang G, Lou C, Dong Y, Yuan Z.
europepmc   +1 more source

Case Report: A case of first-line treatment for rare ROS1 fusion mutation lung adenocarcinoma with entrectinib. [PDF]

Front Oncol
Yang Y, Yi Q, Yang W, Luo Y, Zhang L.
europepmc   +1 more source